An interventional study of Fibersym and Control cookie in Postprandial Hyperglycemia, sponsored by MGP Ingredients, Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-22.
Sponsored by MGP Ingredients, Inc. · Not applicable, Interventional, and Other
Fibersym® is a RS4-type resistant modified wheat starch in which over 85% of the total starch is resistant starch as measured by AOAC method 991.43. It is meant to be consumed on a regular basis and doses up to 33g/day can be tolerated. The effect of a Fibersym-containing meal on postprandial glucose and insulin levels when compared to a control meal, where both meals contain the same amount of available carbohydrate, is not known. This study therefore investigated the acute effect of a Fibersym cookie and a control cookie matched for available carbohydrate after a 3-day habituation period.
The study used a double-blind, randomized, cross-over design.
Visit 1: Participants willing to be considered were invited to come to the research centre to have the study procedures explained to them and be given a copy of the consent form which they may either sign then, take away to sign at a later date, or decline to participate. Participants were encouraged to ask any questions they may have and not to sign the consent form until all of their questions have been answered to their satisfaction. Those who consented to participate came to the research centre for a pre-selection visit when subject eligibility will be determined. A number of parameters were assessed including blood pressure, weight, height, BMI, and brief medical history.
Visit 2-3: Each eligible subject received one of the treatments at visit 2 and the other at visit 3. The order of the 2 treatments was randomized using an online randomization calculator. The interval between visits was no less than 6 days and no more than 4 weeks. Prior to each visit there was a 3-day pre-feeding period during which subjects consumed either 108.9g Control Cookies (approx. 3.5 cookies) per day or 136.2 g of Fibersym Cookies (approx. 4 cookies) per day (delivering 29 g fiber from Fibersym/day) according to the randomized order. Cookies were consumed with each main meal (breakfast, lunch and dinner).
Subjects were provided with a calorie appropriate, standard frozen dinner to be consumed on the evening before each visit. On the day of each visit, participants came to GI Labs in the morning after a 10-12 h overnight fast (except for water). Two (2) fasting fingerprick blood samples were collected at -5 min and 0 min. Each sample consisted of 2 vials, one for glucose analysis and one for insulin analysis (4-8 drops of blood each). Questionnaires to record satiety and GI symptoms were administered. Participants were then a 40g available carbohydrate protion of the same type of cookie (Control or Fibersym) they had been consuming over the past 3 days containing together with 250 ml of water and instructed to consume them over 15 minutes. Additional blood samples were collected 15, 30, 45, 60, 90 and 120 min after the start of the test meal. Satiety questionnaires were administered at the same time intervals. GI symptom questionnaires were filled out at 2 h in addition to fasting.
Test Foods:
The sugar snap cookie formula (Control) was obtained from the American Institute of Baking (AIB) International (Manhattan, KS). Fibersym RW (Appendix 1) was added as an extra portion to the Control Cookie recipe, amounts were adjusted so that both the control and Fibersym cookie portions contained the same amount of available carbohydrate (ingredients are listed in appendix 1). Both cookies were baked at the facilities of AIB. The macronutrient composition of baked cookies was determined by an independent laboratory and the final weights of the cookies fed were adjusted accordingly.
To maintain blinding, the cookies were re-packaged by a GI Labs staff member not involved in the clinical trial. Product label displayed the subject number, subject initials, product ID, ingredients statement, GIL repacked date, expiration date, researcher name and telephone number, investigational use statement, and allergy warnings (if needed). Study Product Intake Logs were completed upon dispensation of study product to each subject. After the data had been entered, checked for errors and the database locked, the code was broken.
Participants were asked to maintain stable dietary and activity habits throughout their participation and to refrain from drinking alcohol and from unusual levels of food intake or physical activity for 24 h before each test. Subjects were asked to complete a 3- day record of supplement consumption and whether they consumed the standard evening meal, in addition to a 3-day symptom diary before each test visit. If any subject was not feeling well or had not complied with the preceding experimental conditions, the test was not carried out and was rescheduled for another day.
699 studies on the registry are indexed under Hyperglycemia; 105 are open to participants now.
This study's enrollment of 16 is below the median of 46 across 521 interventional studies indexed under Hyperglycemia.
Browse Hyperglycemia studies →This is the only study on the registry with MGP Ingredients, Inc. as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
a sugarsnap cookie baked specifically for this trial
Other: Control cookie
a sugarsnap cookie baked using the same methodology for the control cookie but with the resistants starch RS4, Fibersym, added
Other: Fibersym
RS4-type resistant modified wheat starch
control cookie
2-hour Postprandial Glucose Incremental Area Under the Curve (IAUC)
2-hour postprandial glucose incremental area under the curve (IAUC), calculated from blood samples taken 5 min prior to meal, 0, 15, 30, 45, 60, 90 and 120 min after the start of the test meal.
Time frame: 2 hours
2-hour Postprandial Insulin Incremental Area Under the Curve (IAUC)
2-hour postprandial insulin incremental area under the curve (IAUC) calculated from blood samples taken 5 min prior to meal, 0, 15, 30, 45, 60, 90 and 120 min after the start of the test meal.
Time frame: 2 hours
Abdominal Bloating
The occurrence of abdominal bloating (none, mild, moderate or severe) daily before breakfast during the three days of each pre-feeding period and before consuming the test meal on day 4.
Time frame: 4 days
Belching
The occurrence of belching (none, mild, moderate or severe) daily before breakfast during the three days of each pre-feeding period and before consuming the test meal on day 4.
Time frame: 4 days
Nausea
The occurrence of nausea (none, mild, moderate or severe) daily before breakfast during the three days of each pre-feeding period and before consuming the test meal on day 4.
Time frame: 4 days
Diarrhea
The occurrence of diarrhea (none, mild, moderate or severe) daily before breakfast during the three days of each pre-feeding period and before consuming the test meal on day 4.
Time frame: 4 days
Flatulence
The occurrence of flatulence (none, mild, moderate or severe) daily before breakfast during the three days of each pre-feeding period and before consuming the test meal on day 4.
Time frame: 4 days
Satiety Scores
Satiety is the mean of 4 measures, hunger (H), fullness (F), desire to eat (D) and prospective consumption (how much do you think you can eat) (P) each measured using visual analogue scales (VAS) at intervals over the postprandial period. A VAS is a 100mm line anchored at the right end with phrase indicating a high in tensity of the feeling (eg. as hungry as I have ever felt) and at the left other end with a phrase indicating a low intensity of feeling (eg. not hungry at all). For each measure the minimum score is 0 and the maximum score is 100, as measured in mm from the left end. Higher scores mean more hungry, less full, more desire to eat and high prospective consumption (can eat a large amount). The mean score is calculated as (H - F + D + P)/4.
Time frame: 2 hours
| Milestone | Experimental: Control Cookie, Then Fibersym Cookie | Fibersym Cookie First |
|---|---|---|
| Started | 10 | 6 |
| Completed | 9 | 6 |
| Not completed | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
2-hour postprandial glucose incremental area under the curve (IAUC), calculated from blood samples taken 5 min prior to meal, 0, 15, 30, 45, 60, 90 and 120 min after the start of the test meal.
| mmol*min/L | Control Cookie | Fibersym Cookie |
|---|---|---|
| 2-hour Postprandial Glucose Incremental Area Under the Curve (IAUC) | 124 ± 16 | 106 ± 16 |
2-hour postprandial insulin incremental area under the curve (IAUC) calculated from blood samples taken 5 min prior to meal, 0, 15, 30, 45, 60, 90 and 120 min after the start of the test meal.
| pmol*h/L | Control Cookie | Fibersym Cookie |
|---|---|---|
| 2-hour Postprandial Insulin Incremental Area Under the Curve (IAUC) | 245 ± 24 | 189 ± 21 |
The occurrence of abdominal bloating (none, mild, moderate or severe) daily before breakfast during the three days of each pre-feeding period and before consuming the test meal on day 4.
| Participants | Control Cookie | Fibersym Cookie |
|---|---|---|
| Abdominal Bloating | 8 | 8 |
The occurrence of belching (none, mild, moderate or severe) daily before breakfast during the three days of each pre-feeding period and before consuming the test meal on day 4.
| Participants | Control Cookie | Fibersym Cookie |
|---|---|---|
| Belching | 9 | 10 |
The occurrence of nausea (none, mild, moderate or severe) daily before breakfast during the three days of each pre-feeding period and before consuming the test meal on day 4.
| Participants | Control Cookie | Fibersym Cookie |
|---|---|---|
| Nausea | 8 | 9 |
The occurrence of diarrhea (none, mild, moderate or severe) daily before breakfast during the three days of each pre-feeding period and before consuming the test meal on day 4.
| Participants | Control Cookie | Fibersym Cookie |
|---|---|---|
| Diarrhea | 6 | 7 |
The occurrence of flatulence (none, mild, moderate or severe) daily before breakfast during the three days of each pre-feeding period and before consuming the test meal on day 4.
| Participants | Control Cookie | Fibersym Cookie |
|---|---|---|
| Flatulence | 11 | 12 |
Satiety is the mean of 4 measures, hunger (H), fullness (F), desire to eat (D) and prospective consumption (how much do you think you can eat) (P) each measured using visual analogue scales (VAS) at intervals over the postprandial period. A VAS is a 100mm line anchored at the right end with phrase indicating a high in tensity of the feeling (eg. as hungry as I have ever felt) and at the left other end with a phrase indicating a low intensity of feeling (eg. not hungry at all). For each measure the minimum score is 0 and the maximum score is 100, as measured in mm from the left end. Higher scores mean more hungry, less full, more desire to eat and high prospective consumption (can eat a large amount). The mean score is calculated as (H - F + D + P)/4.
| mm | Control Cookie | Fibersym Cookie |
|---|---|---|
| Satiety Scores | 79 ± 9 | 70 ± 8 |
Incremental area under the curve from 0 to 90 min calculated from blood samples taken 5 min prior to meal, 0, 15, 30, 45, 60 and 90 min after the start of the test meal.
| mmol*min/L | Control Cookie | Fibersym Cookie |
|---|---|---|
| 0-90min Incremental Area Under the Glucose Curve | 108 ± 13 | 87 ± 12 |
Incremental area under the curve from 0 to 90 min calculated from blood samples taken 5 min prior to meal, 0, 15, 30, 45, 60 and 90 min after the start of the test meal.
| pmol*h/L | Control Cookie | Fibersym Cookie |
|---|---|---|
| 0-90min Incremental Area Under the Insulin Curve | 216 ± 21 | 162 ± 18 |
Difference between fasting and maximum glucose concentration during the test
| mmol/L | Control Cookie | Fibersym Cookie |
|---|---|---|
| Glucose Peak Rise | 2.20 ± 0.24 | 1.72 ± 0.23 |
Collected over 1 month. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Control Cookie | 0/16 (0%) | 0/16 (0%) | 1/16 (6.3%) |
| Fibersym Cookie | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) |
| Event | Control Cookie | Fibersym Cookie |
|---|---|---|
| InfectionRespiratory, thoracic and mediastinal disorders | 1/16 | 0/15 |
15 completed the cross-over study successfully and all were included in the analysis
| Age, Continuous(years) | Control Cookie First Followed by Fibersym Cookie | Fibersym Cookie First Followed by Control Cookie | Total |
|---|---|---|---|
| Mean | 33 ± 12 | 29 ± 8 | 31 ± 11 |
| Sex: Female, Male(Participants) | Control Cookie First Followed by Fibersym Cookie | Fibersym Cookie First Followed by Control Cookie | Total |
|---|---|---|---|
| Female | 6 | 4 | 10 |
| Male | 4 | 2 | 6 |
| Race (NIH/OMB)(Participants) | Control Cookie First Followed by Fibersym Cookie | Fibersym Cookie First Followed by Control Cookie | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 3 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 6 | 3 | 9 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Control Cookie First Followed by Fibersym Cookie | Fibersym Cookie First Followed by Control Cookie | Total |
|---|---|---|---|
| Canada | 10 | 6 | 16 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.